Skip Navigation

Continuing Education in Anaesthesia, Critical Care & Pain 2005 5(2):65-66; doi:10.1093/bjaceaccp/mki018
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Continuing Education in Anaesthesia, Critical Care & Pain | Volume 5 Number 2 2005 © The Board of Management and Trustees of the British Journal of Anaesthesia [2005]. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Multiple Choice Questions

The first 10% of the full text of this article appears below.

27. Regarding post-dural puncture headache (PDPH):
  1. The incidence of PDPH is lower with 29G needles than 25G needles.
  2. PDPH most commonly presents 5–14 days after the procedure.
  3. PDPH can be treated with the 5-HT1D receptor agonist Sumatriptan.
  4. To be effective, epidural blood patch must be performed within 72 h.
  5. Epidural blood patch may cause failure of subsequent epidural analgesia.

28. Transient neurological symptoms:
  1. Are more common after intrathecal bupivacaine than lidocaine.
  2. Are more common when patients are placed in lithotomy.
  3. May progress to permanent neurological dysfunction.
  4. Are more common with glucose containing solutions of local anaesthetics.
  5. Rarely persist longer than 1 month.

29. Ropivacaine:
  1. Is an ester local anaesthetic agent.
  2. Is licensed for . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?